Tango Therapeutics, Inc.

NasdaqGM:TNGX 株式レポート

時価総額：US$3.1b

Tango Therapeutics マネジメント

マネジメント 基準チェック /24

Tango Therapeuticsの CEO はMalte Petersで、 Jan2026年に任命され、 の在任期間は 1 年未満です。 は、会社の株式の0.008%を直接所有しており、その価値は$ 243.30K 。経営陣と取締役会の平均在任期間はそれぞれ0.3年と5.3年です。

主要情報

Malte Peters

最高経営責任者

US$1.2m

報酬総額

CEO給与比率n/a
CEO在任期間less than a year
CEOの所有権0.008%
経営陣の平均在職期間less than a year
取締役会の平均在任期間5.3yrs

経営陣の近況

Recent updates

Seeking Alpha • May 17

Tango Therapeutics: 'Hold' On Combination Strategy Shift Of Vopimetostat

Summary Tango Therapeutics is downgraded from "Buy" to "Hold" due to a major, unproven strategy shift for vopimetostat. The company now prioritizes combination trials of vopimetostat with RAS[ON] inhibitors for 1st-line MTAP-del pancreatic cancer, with pivotal trial design pending new data. Upcoming catalysts include phase 1/2 data for vopimetostat in lung cancer and TNG456 in glioblastoma, but outcomes remain uncertain. With $379.8M cash on hand, the company has enough to fund its operations through 2028. Read the full article on Seeking Alpha
分析記事 • Jan 19

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders have had their patience rewarded with a 53% share price jump in...
分析記事 • Dec 05

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 32%

Despite an already strong run, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have been powering on, with a gain of...
分析記事 • Sep 17

Tango Therapeutics, Inc. (NASDAQ:TNGX) Investors Are Less Pessimistic Than Expected

With a price-to-sales (or "P/S") ratio of 33.7x Tango Therapeutics, Inc. ( NASDAQ:TNGX ) may be sending very bearish...
分析記事 • May 15

US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results

The analysts might have been a bit too bullish on Tango Therapeutics, Inc. ( NASDAQ:TNGX ), given that the company fell...
分析記事 • Apr 14

Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding

Unfortunately for some shareholders, the Tango Therapeutics, Inc. ( NASDAQ:TNGX ) share price has dived 28% in the last...
分析記事 • Apr 04

Here's Why We're Watching Tango Therapeutics' (NASDAQ:TNGX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Feb 28

Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares are down a considerable 30% in...
分析記事 • Feb 28

Tango Therapeutics, Inc. (NASDAQ:TNGX) Not Doing Enough For Some Investors As Its Shares Slump 30%

To the annoyance of some shareholders, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares are down a considerable 30% in...
Seeking Alpha • Jan 23

Tango Therapeutics: Chance For A Short Squeeze

Summary Tango Therapeutics is a growing cancer drug development company with partners such as Gilead Sciences. Given the high short interest and the low number of shares outstanding, I expect a short squeeze to occur, which could lead to an increase in TNGX's share price thereafter. Despite the negative sentiment, recent institutional selling and call option activity suggest potential value accumulation and positive momentum for TNGX. I decided to buy OTM call options on TNGX due to the low implied volatility. Read the full article on Seeking Alpha
分析記事 • Dec 05

Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Oct 31

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Unfortunately for some shareholders, the Tango Therapeutics, Inc. ( NASDAQ:TNGX ) share price has dived 26% in the last...
Seeking Alpha • Sep 10

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Summary Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors' PRMT5 data, with recent fluctuations driven by Amgen and Mirati's clinical results. Tango's financial stability is supported by >$300M in cash, a Gilead partnership, and a funding runway until 2027, covering key clinical readouts. Despite the high risk, Tango's differentiated approach and potential blockbuster candidates make TNGX stock an intriguing speculative buy ahead of critical data readouts. Read the full article on Seeking Alpha
分析記事 • Sep 01

What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have continued their recent momentum with a 29% gain in the last month...
分析記事 • Jun 29

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have had a really impressive month, gaining 27% after a shaky period...
分析記事 • May 30

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Key Insights Tango Therapeutics will host its Annual General Meeting on 5th of June Salary of US$626.0k is part of CEO...
分析記事 • Mar 19

Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have had a horrible month, losing 30% after a relatively good period...
分析記事 • Mar 06

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Tango Therapeutics...
分析記事 • Jan 08

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

You may think that with a price-to-sales (or "P/S") ratio of 25x Tango Therapeutics, Inc. ( NASDAQ:TNGX ) is a stock to...
分析記事 • Nov 09

Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

Shareholders in Tango Therapeutics, Inc. ( NASDAQ:TNGX ) may be thrilled to learn that the analysts have just delivered...
分析記事 • Aug 12

New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders will have a reason to smile today, with the analysts making...
分析記事 • May 10

Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Oct 20

Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer

H.C. Wainwright has started Tango Therapeutics (NASDAQ:TNGX) with a buy rating citing its use of synthetic lethality to develop cancer candidates. The firm has a $10 price target (~43% upside based on Wednesday's close). Analyst Robert Burns said that the targets the company is focused on could potentially treat large patient populations. He cited TNG908, Tango's (TNGX) most advanced candidate, currently in phase 1/2 for MTAP-deleted tumors. Initial data is expected in H1 2023. After determining the optimum dose for TNG908, Tango (TNGX) says it will evaluate efficacy in multiple tumor types in specific cohorts, including malignant peripheral nerve sheath tumor, non-small cell lung cancer, mesothelioma, cholangiocarcinoma, and glioblastoma. Seeking Alpha's Quant Rating views Tango (TNGX) as a buy with high marks for growth and momentum.
分析記事 • Oct 05

Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
分析記事 • Aug 13

Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

The investors in Tango Therapeutics, Inc. 's ( NASDAQ:TNGX ) will be rubbing their hands together with glee today...
Seeking Alpha • Aug 10

Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M

Tango Therapeutics press release (NASDAQ:TNGX): Q2 GAAP EPS of -$0.28 beats by $0.03. Revenue of $5.78M (-68.2% Y/Y) beats by $0.12M.
分析記事 • May 28

We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Jan 06

We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

CEO

Malte Peters (63 yo)

less than a year
在職期間
US$1,151,381
報酬

Dr. Malte Peters, MD., is Director at HOOKIPA Pharma Inc. since 2023 and is its Chief Executive Officer since July 22, 2024 and served as its Ad Interim Senior Clinical Advisor from September 2023 until Ma...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Barbara Weber
Founder & Executive Chair9.2yrsUS$2.82m1.07%
$ 33.5m
Malte Peters
Presidentless than a yearUS$1.15m0.0078%
$ 243.3k
Daniella Beckman
Executive Officerno dataUS$1.16m0.091%
$ 2.8m
Adam Crystal
President of Research & Development3.3yrsUS$1.72m0.078%
$ 2.4m
Alan Ashworth
Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
William Kaelin
Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Antoni Ribas
Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Matthew Gall
Chief Financial Officerless than a yearデータなしデータなし
Jannik Andersen
Chief Scientific Officer2.6yrsデータなしデータなし
Julie Fogarty
Vice President of Legal & Corporate Secretaryno dataデータなしデータなし
Julie Carretero
Chief Human Resources Officer2.2yrsデータなしデータなし
Philippe Serrano
Chief Regulatory Officerless than a yearデータなしデータなし
0.3yrs
平均在職期間
58yo
平均年齢

経験豊富な経営陣: TNGXの経営陣は 経験豊富 とはみなされません ( 0.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称ポジション在職期間報酬所有権
Barbara Weber
Founder & Executive Chair9.2yrsUS$2.82m1.07%
$ 33.5m
Malte Peters
President7.7yrsUS$1.15m0.0078%
$ 243.3k
Alan Ashworth
Founder & Member of Scientific Advisory Board5.3yrsデータなしデータなし
William Kaelin
Founder & Member of Scientific Advisory Board5.3yrsデータなしデータなし
Antoni Ribas
Founder & Member of Scientific Advisory Board5.3yrsデータなしデータなし
Mace Rothenberg
Independent Director5.2yrsUS$169.70k0.0078%
$ 243.3k
Lesley Calhoun
Independent Director5.2yrsUS$176.33k0.0043%
$ 135.1k
John Ketchum
Independent Director2.8yrsUS$196.14k0.0078%
$ 245.5k
Sung Lee
Lead Independent Directorless than a yearデータなし0%
$ 0
Alan Huang
Member of Scientific Advisory Board1.3yrsUS$1.88mデータなし
5.3yrs
平均在職期間
63.5yo
平均年齢

経験豊富なボード: TNGXの 取締役会 は 経験豊富 であると考えられます ( 5.3年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/22 11:03
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Tango Therapeutics, Inc. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14

アナリスト機関
Yuan ZhiB. Riley Securities, Inc.
John NewmanCanaccord Genuity
Eric SchmidtCantor Fitzgerald & Co.